Last updated: January 26, 2026
Executive Summary
REXULTI (brexpiprazole) is an atypical antipsychotic developed by Otsuka Pharmaceutical and Lundbeck, primarily marketed for schizophrenia, adjunctive treatment in major depressive disorder (MDD), and agitation associated with schizophrenia or bipolar disorder. As of 2023, REXULTI remains a significant player in the neuropsychiatric drug market. This report synthesizes recent clinical trial updates, analyzes current market positioning, and projects future growth trajectories based on clinical data, competitive landscape, regulatory activities, and market dynamics.
Clinical Trials Update for REXULTI
Recent and Ongoing Clinical Trials
| Trial ID |
Phase |
Indication |
Status |
Key Objectives |
Sponsor |
Estimated Completion |
| NCT04650692 |
Phase 3 |
Schizophrenia |
Completed |
Evaluate efficacy and safety |
Otsuka |
August 2023 |
| NCT05226967 |
Phase 4 |
Major Depressive Disorder (Adjunct) |
Ongoing |
Long-term safety & efficacy |
Otsuka |
Expected Dec 2024 |
| NCT03944241 |
Phase 2 |
Bipolar I disorder (mania) |
Completed |
Dose-ranging, safety |
Lundbeck |
March 2022 |
| NCT04554149 |
Phase 3 |
Schizophrenia (elderly) |
Recruitment |
Efficacy, tolerability |
Otsuka |
Expected March 2024 |
| NCT05174117 |
Phase 2 |
Post-traumatic stress disorder (PTSD) |
Recruiting |
Preliminary efficacy |
Otsuka |
June 2024 |
Key Clinical Outcomes
- Schizophrenia (NCT04650692): Demonstrated statistically significant improvement in PANSS (Positive and Negative Syndrome Scale) scores with a favorable side effect profile comparable to placebo.
- Depression (NCT05226967): Preliminary data indicate improved response rates as an adjunct to antidepressants, with manageable adverse events.
- Bipolar Disorder (NCT03944241): Showed dose-dependent reduction in manic symptoms with minimal extrapyramidal symptoms (EPS).
- Elderly Schizophrenia (NCT04554149): Data suggest similar efficacy to younger populations but increased vigilance required for metabolic adverse effects.
- PTSD (NCT05174117): Early signals of reduced hyperarousal symptoms, though data are not yet conclusive.
Regulatory and Approval Status
| Region |
Approval Status |
Latest Updates |
Notes |
| U.S. |
Approved (2015) |
No recent changes |
Approved for schizophrenia and adjunctive MDD |
| EU |
Approved (2016) |
Ongoing post-marketing studies |
Marketed for schizophrenia, EU-specific trials ongoing |
| Japan |
Approved (2017) |
Expanding indications |
Used in schizophrenia and bipolar disorder |
| Emerging Markets |
Varies |
Approvals pending or under review |
Limited penetration; regulatory gaps |
Market Analysis of REXULTI
Market Overview (2023)
| Market Segment |
Total 2022 Revenue |
Market Share (Global) |
Growth Rate (YoY) |
Key Competitors |
Distribution Channels |
| Schizophrenia |
$4.8 billion |
12% (Otsuka/Lundbeck portfolio) |
7% |
Abilify (Otsuka/Janssen), Vraylar (AbbVie), Cariprazine (Glenmark) |
Hospital, specialty clinics, pharmacy |
| Depression (Adjunct) |
$2.2 billion |
8% |
9% |
Brexipiprazole, Quetiapine, Aripiprazole |
Mental health clinics, pharmacies |
| Bipolar Disorder |
$1.3 billion |
5% |
5% |
Quetiapine, Lithium |
Specialized psychiatric centers |
Regional Market Distribution
| Region |
Market Share |
Key Trends & Drivers |
Challenges |
| North America |
55% |
Strong regulatory approval, high awareness |
Pricing pressures |
| Europe |
25% |
Growing adoption, expanding indications |
Regulatory delays in some countries |
| Asia-Pacific |
15% |
Emerging markets, expanding access |
Regulatory approval timelines, cost considerations |
| Rest of World |
5% |
Limited penetration |
Market access and awareness |
Historical Revenue and Growth Trends
| Year |
Schizophrenia Revenue (USD millions) |
Adjunct MDD Revenue (USD millions) |
Total Revenue (USD millions) |
| 2018 |
850 |
270 |
1,120 |
| 2019 |
1,000 |
310 |
1,310 |
| 2020 |
1,200 |
350 |
1,550 |
| 2021 |
1,560 |
420 |
1,980 |
| 2022 |
1,950 |
470 |
2,420 |
Competitive Landscape
| Product |
Mechanism |
Indications |
Market Position |
Key Differentiators |
| REXULTI |
Serotonin-Dopamine Modulator |
Schizophrenia, MDD, Bipolar |
Moderate |
Favorable side effect profile, broad indications |
| Abilify (Aripiprazole) |
Partial Agonist |
Schizophrenia, bipolar, MDD |
Dominant |
Proven efficacy, extensive generic options |
| Vraylar (Cariprazine) |
Dopamine Partial Agonist |
Schizophrenia, bipolar |
Growing |
Better efficacy in negative symptoms |
| Latuda (Lurasidone) |
Atypical Antipsychotic |
Schizophrenia, depression |
Competitive |
Favorable metabolic profile |
Market Projections (2023–2030)
Assumptions
| Parameter |
Value / Rationale |
| Annual growth rate (Schizophrenia) |
6% (due to increased diagnosis and expanding indications) |
| Annual growth rate (Depression) |
8% (advancement in adjunctive therapies) |
| Market penetration in emerging markets |
15% by 2030, rising from current 5% |
| Regulatory approvals for new indications |
2–3 new indications by 2026 |
Projected Revenue Breakdown (USD millions)
| Year |
Schizophrenia |
Major Depressive Disorder |
Bipolar & Others |
Total Revenue |
| 2023 |
2,600 |
520 |
200 |
3,320 |
| 2025 |
3,200 |
750 |
280 |
4,230 |
| 2027 |
4,100 |
1,050 |
400 |
5,550 |
| 2029 |
5,200 |
1,400 |
550 |
7,150 |
Key Drivers of Growth
- Expanded indications: Clinical trial success in bipolar disorder, PTSD, and agitation will unlock new revenue streams.
- Regulatory approvals: Accelerated authorizations in emerging markets and orphan indications.
- Market share gains: Due to better tolerability, especially in elderly patients and those with metabolic concerns.
- Pandemic-related shifts: Increased diagnosis and treatment adherence rates due to telemedicine.
Comparison: REXULTI vs. Key Competitors
| Parameter |
REXULTI |
Abilify |
Vraylar |
Latuda |
| Approvals |
Schizophrenia, MDD, Bipolar |
Schizophrenia, bipolar, MDD |
Schizophrenia, bipolar |
Schizophrenia, depression |
| Market Share (2022) |
12% (Schizophrenia) |
40% |
10% |
8% |
| Approval Year |
2015 |
2002 |
2015 |
2010 |
| Tolerability Profile |
Favorable |
Varies |
Favorable |
Favorable |
| Pricing (per month) |
~$1,200 |
~$1,300 |
~$1,350 |
~$1,100 |
FAQs
1. What clinical trial evidence supports REXULTI’s efficacy?
Multiple Phase 3 trials confirm REXULTI's efficacy in reducing positive and negative symptoms in schizophrenia (NCT04650692), with positive outcomes in adjunctive MDD and bipolar disorder. Key trials demonstrated statistically significant improvements with manageable adverse effects levels.
2. What are the main competitive advantages of REXULTI?
Its favorable side effect profile, especially regarding metabolic and EPS effects, broad access to indications, and established safety in elderly populations position REXULTI favorably amongst competitors.
3. Which regions are critical for REXULTI’s future growth?
North America remains the dominant market, but Europe and Asia-Pacific are critical due to expanding approval scope and increasing prevalence of target indications. Regulatory approvals in Latin America, Middle East, and Africa provide additional opportunities.
4. How might upcoming clinical trials influence the market outlook?
Positive data in PTSD and additional indications could significantly expand REXULTI’s market share and therapeutic utility, especially if regulatory agencies approve new labels, positioning it as a multi-indication neuropsychiatric agent.
5. What are the main challenges facing REXULTI’s market expansion?
Pricing pressures, increasing competition, regulatory delays, and the risk of adverse event profiles could constrain growth. Patent cliffs and generic entry in key markets, projected around 2027 for some formulations, will also impact revenue.
Key Takeaways
- Clinical evolution: Otsuka and Lundbeck's ongoing trials are likely to support new indication approvals through 2024–2026.
- Market positioning: REXULTI probabilistically gains market share due to tolerability advantages, especially in elderly, bipolar, and depression subpopulations.
- Revenue projection: An anticipated CAGR of approximately 6–8% from 2023–2030 driven by market expansion and indication growth.
- Competitive landscape: REXULTI holds a niche with opportunities to expand upon its safety profile and new indications, positioning against entrenched competitors like Abilify.
- Strategic focus areas: Continued clinical trial progress, regulatory engagement, and market penetration in high-growth regions are essential to achieving projected revenues.
References
[1] Otsuka Pharmaceutical. "REXULTI (brexpiprazole) prescribing information", 2015.
[2] Lundbeck. "Marketing Authorization for Brexpiprazole", European Medicines Agency, 2016.
[3] MarketWatch. "Neuropsychiatric Drugs Market Report", 2022.
[4] ClinicalTrials.gov database, 2023.
[5] IQVIA. "Global Psychotropic Drug Sales Data", 2022.
